Skip to content
value.today

Clovis Oncology

CLVSUnlisted company
$302 Mlast known market cap, Jan 2022 — no current value
Compare
World rank
—
no current market cap
Revenue
$149 M
For year ending December-2021
Net income
$-265 M
-177.8% margin
SEC filing
Employees
—

Clovis Oncology in brief

Clovis Oncology is an unlisted company in the Biotechnology industry, based in Boulder, Colorado, USA. It was founded in 2009. In the year to December 2021 it had sales of $149 M and a net loss of $265 M.

Written from the figures on this page, so it changes when they do. The date of each figure is under How current the figures are.

About Clovis Oncology

Clovis Oncology is an American pharmaceutical company which mainly markets products for treatment in oncology. Clovis was founded in 2009 and is headquartered in Boulder, Colorado. The company is a publicly traded company on NASDAQ under the symbol CLVS and is in the NASDAQ Biotechnology Index with several products in its product pipeline. As of December 31, 2017, the company was not profitable and had incurred losses in each year since its inception in April 2009. In December 2022, Clovis Oncology filed for Chapter 11 bankruptcy.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Clovis Oncology timeline

4 events, 2009–2020
  1. 2009
  2. 🏁
    · approximate
    Founded
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2011
  5. 🔔
    · approximate
    Initial public offering on Nasdaq as CLVS
  6. 2020
  7. 💰
    Record revenue of $165 million
    FY2020, the highest of the 4 years on record.

Events of Clovis Oncology from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about Clovis Oncology

Acquisitions and changes
Delisted: it ended its SEC registration (Form 15) on 11 July 2023.

Market cap history

$0 M$148 M$296 M$445 M$593 M202020212022

World rank over time

▼ down 6,074 places since 2020
2020-01-01: #10550#10,55020202021-01-01: #11190#11,19020212022-01-07: #16624#16,6242022

Rank in USA: #2,408 (Jan 2020) · #2,752 (Jan 2021) · #3,463 (Jan 2022)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
—
Price / book
—
Free cash flow yield
—
Net margin (TTM)
-177.8%
Operating margin
-151.8%
Return on equity
—
Liabilities / assets
159.0%
Net debt
$366M
Revenue growth
-9.6%
R&D / revenue
125.4%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2014: revenue $14M, net income $-160M$14MFY14Fiscal year ending Dec 2015: revenue —, net income $-353M—FY15Fiscal year ending Dec 2016: revenue $0M, net income $-349M$0MFY16Fiscal year ending Dec 2017: revenue $56M, net income $-346M$56MFY17Fiscal year ending Dec 2018: revenue $95M, net income $-368M$95MFY18Fiscal year ending Dec 2019: revenue $143M, net income $-400M$143MFY19Fiscal year ending Dec 2020: revenue $165M, net income $-369M$165MFY20Fiscal year ending Dec 2021: revenue $149M, net income $-265M$149MFY21
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2021$149M-9.6%$-226M$-265M-177.8%
Dec 2020$165M+15.0%$-302M$-369M-224.4%
Dec 2019$143M+49.9%$-377M$-400M-280.0%
Dec 2018$95M+71.8%$-334M$-368M-385.8%
Dec 2017$56M+69287.5%$-238M$-346M-624.0%
Dec 2016$0M—$-373M$-349M-436425.0%
Dec 2015——$-377M$-353M—
Dec 2014$14M—$-158M$-160M-1175.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2021$-196M$0M$-196M$-2.29—
Dec 2020$-253M$0M$-253M$-4.38—
Dec 2019$-324M$3M$-327M$-7.43—
Dec 2018$-366M$9M$-375M$-7.07—
Dec 2017$-261M$0M$-261M$-7.36—
Dec 2016$-267M$1M$-267M$-9.07—
Dec 2015$-253M$3M$-256M$-9.79—
Dec 2014$-117M$2M$-119M$-4.72—

SEC filings

Official filings of Clovis Oncology with the US Securities and Exchange Commission.

Annual results

Revenue
$149 M
Operating income
$-226 M
Net income
$-265 M

For year ending December-2021 · source: SEC filing

Balance sheet

Total assets
$473 M
Total liabilities
$752 M
Total equity
$-279 M

As of December-2021

Insider trading at Clovis Oncology#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
37
since
Clovis Oncology: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Gillian C. IVers-ReadSee RemarksSell-1,675$0.980$2 K290,993Form 4
filed Thomas C. HardingSee RemarksSell-788$0.980$77218,590Form 4
filed Lindsey RolfeSee RemarksSell-1,908$0.980$2 K111,419Form 4
filed Daniel W. MuehlSee RemarksSell-2,513$0.980$2 K102,271Form 4
filed Paul Edward GrossSee RemarksSell-2,595$0.980$3 K95,840Form 4
filed Daniel W. MuehlSee RemarksSell-2,066$0.980$2 K104,830Form 4
filed Gillian C. IVers-ReadSee RemarksSell-2,006$0.980$2 K293,612Form 4
filed Paul Edward GrossSee RemarksSell-2,135$0.980$2 K98,330Form 4

Markets and events: Clovis Oncology#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Bankruptcy filing: (8-K); (8-K)

Clovis Oncology scorecard#

Passes 6 of the 14 checks that could be worked out: strongest in growth (4 of 6), weakest in profitability (1 of 4). Fiscal year 2021.

  • Valuationnot known
  • Growth4 of 6
  • Profitability1 of 4
  • Financial health1 of 3
  • Shareholder returns0 of 1

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 20, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Clovis Oncology: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Clovis Oncology: statements by fiscal year
PeriodTrendFY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016FY 2015to Dec 31, 2015FY 2014to Dec 31, 2014FY 2013to Dec 31, 2013FY 2012to Dec 31, 2012
Income statement
Revenue14916514395560.1014——
Cost of revenue—————0.100——
Research and development1872582832311422512691386759
Selling, general and administrative128164183176139413121——
General and administrative——————31211711
Operating expenses—4675204292933733771728474
Total costs and expenses375467520———————
Operating income−226−302−377−334−238−373−377−158−84−74
Interest expense and finance costs34311913108.58.42.6——
Other non-operating income (expense)−39−68−22−34−112−8.4−5.20.7−0.7−0.2
Income before tax−265−370−399−367−350−381−382−158−84−74
Income tax−0.4−0.51.80.6−3.6−32−292.30.1−0.0
Net income including minority interests−265−369−400−368−346−349−353———
Net income attributable to shareholders−265−369−400−368−346−349−353−160−85−74
Earnings per share, basic-2.29-4.38-7.43-7.07-7.36-9.07-9.79-4.72-2.95-2.97
Earnings per share, diluted-2.29-4.38-7.43-7.07-7.36-9.07-9.79-4.72-2.95-2.97
Shares, weighted average (basic)1168454———————
Shares, weighted average (diluted)116845452473836342925
Balance sheet
Cash and cash equivalents143240162222464216279483323144
Short-term investments——135298100—————
Receivables272721136.20.10———
Inventory14312727280————
Other current assets129.1198.67.56.77.74.74.40.7
Current assets198311366572627279540491329145
Property, plant and equipment6.61215274.04.44.92.71.01.1
Goodwill636363636557596675—
Other intangible assets606663522021102213245—
Total assets473606670864735365713777r650146
Accounts payable272732291511112.94.42.3
Current liabilities1251851331268266r76482112
Non-current liabilities—————————0.3
Total liabilities752764844717368368413446r15212
Retained earnings−2,877−2,613−2,244−1,843−1,477−1,131−782−429−269—
Shareholders' equity−279−159−174r146368r−3.6r301332498133
Total liabilities and equity473606670864735365713777r650146
Shares outstanding1291045553513938343426
Cash-flow statement
Depreciation and amortization8.58.27.84.62.51.10.80.4r0.30.4
Share-based compensation25515449454040229.54.9
Cash from operating activities−196−253−324−366−261−267−253−117−72−65
Capital expenditure−0.3−0.4−3.3−9.2−0.5−0.8−3.0−2.3−0.1−1.1
Acquisitions, net of cash acquired————————−9.9—
Cash from investing activities−0.3126143−264−54199−255−2.3−100.9
Shares issued117247—945460299025970
Cash from financing activities1002041203885625.230427926170
Exchange-rate effect on cash————0.9−0.4−0.8−0.70.00.0
Change in cash−9778−60−242248−63−2041591795.9
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

As of Sep 30, 2022

Events at Clovis Oncology#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Bankruptcy or receivership 2 · Delisting notice 1 · Debt called early 2 · Change in control 1 · Acquisition or sale completed 2 · Directors and officers 4 · Material agreement 5 · New debt 3 · Shareholder rights changed 2 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 6

Clovis Oncology: events reported to the SEC
FiledWhat happenedFiling
Bankruptcy or receivershipChange in controlDirectors and officersShareholder rights changed8-K
Shareholder rights changed8-K
Acquisition or sale completed8-K
Acquisition or sale completed8-K
Material agreement8-K
Directors and officers8-K
Material agreementNew debt8-K
New debt8-K
Bankruptcy or receivershipDebt called earlyMaterial agreementNew debt8-K
Delisting notice8-K
Debt called early8-K
Results announced8-K
Shareholder vote8-K/A
Bylaws or fiscal year changed8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K/A
Directors and officersShareholder vote8-K
Material agreement8-K

As of Jul 11, 2023

Acquisitions and funding#

1 acquisitions, $185 M paid where reported · 1 private funding rounds before listing

Businesses it acquired

Acquisitions by Clovis Oncology
AcquiredAcquisition dateCompletionPriceStakeSource
Ethical Oncology Science, S.p.A2013—$185 M—Annual report

Private share sales · funding history

Private share sales of Clovis Oncology
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2013$192 MIssued in a merger or acquisition$50 to $250 million9equitySEC
May 2009$146 MNo. 1$50 to $250 million19equitySEC

H-1B hiring at Clovis Oncology#

1 labor condition applications certified in fiscal 2022 for 1 positions, at a median wage of $234 K a year.

Certified, FY2022
1
#2,002 among companies on value.today
Worker positions
1
Median wage offered
$234 K
a year, full-time
Applications filed
1
Clovis Oncology: most frequent H-1B job titles in fiscal 2022
Job titlePositionsMedian wage offered
Director, Pharmacovigilance Global Clinical Trials OperationNatural Sciences Managers1$234 K

Where: Oakland, CA 1

How Clovis Oncology compares in Biotechnology

  • Revenue$149 M · higher than 73% of 649
  • Net margin-177.8% · higher than 31% of 407
  • Revenue growth-9.6% · higher than 35% of 441

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Clovis Oncology🇺🇸$302 M—-177.8%-9.6%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

How current the figures are

Market cap:
Jan 7, 2022 (last known)
Annual results:
For year ending December-2021
Balance sheet:
As of December-2021
Profile updated:
Nov 22, 2026

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Clovis Oncology? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Clovis Oncology's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Clovis Oncology? Suggest a correction